Lunai Bioworks Inc.

As of September 30, 2025, Lunai Bioworks Inc. has 23.18M shares outstanding.

These figures are as of September 30, 2025.

These figures are as of September 30, 2025. Lunai Bioworks Inc. trades at an EV/FCF ratio of 0.05, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of September 30, 2025, Lunai Bioworks Inc. maintains a current ratio of 0.04, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -20.76, indicating conservative leverage, while an interest coverage ratio of -24.64 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended September 30, 2025. Return on assets (ROA) is negative at -203.39, reflecting losses generated across the asset base. Return on capital employed (ROCE) is negative at -62.23, pointing to unprofitable operations over the period.

These figures cover the twelve months ended September 30, 2025. Free cash flow yield is negative at -27.64: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -29.60, meaning Lunai Bioworks Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Lunai Bioworks Inc.'s most recent stock split took place on September 30, 2025 with a 10:1 split ratio.

As of September 30, 2025, Lunai Bioworks Inc. has an Altman Z-Score of -927.25, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.